After hours: 5:00PM EDT
|Bid||3.7600 x 1100|
|Ask||4.0900 x 4000|
|Day's Range||3.9300 - 4.2150|
|52 Week Range||3.5700 - 16.3500|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.20|
BERKELEY, Calif., June 03, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim.
Progression Free Survival (PFS) rate of 18-months in 72% of patientsClinical efficacy in patients with immunologically cold tumor at baselineThe combination of SD-101 and.
24% overall response rate in ITT populationResponses were observed in SD-101 injected and non-injected lesions The combination of SD-101 and pembrolizumab was well-tolerated.
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...
The company is returning its focus to its easier-to-take hepatitis B vaccine and other vaccine work.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
Dynavax Technologies Corp. said late Thursday it will focus on its vaccine business and on its first commercial product, a hepatitis B vaccine, looking to unwind its immuno-oncology business. The company will also lay off workers and trim operations to focus on the vaccine's commercialization. "Following a comprehensive analysis of our assets, strengths and opportunities, we have determined we should focus our resources on our approved vaccine, HEPLISAV-B, which, as the only two-dose hepatitis B vaccine, is gaining market share and is well positioned to become the new standard of care in the U.S," Chief Executive Eddie Gray said. In the same press release, Gray said that the restructuring was "the optimal time" for his retirement, effective Aug. 1. The company's board of directors has created an interim office of the president and has appointed David Novack and Ryan Spencer, two senior vice presidents, as co-presidents effective immediately. Shares of Dynavax, halted earlier in the extended session, fell more than 5% when they resumed trading. The shares ended the regular session 0.2% lower.
Dynavax Technologies Corporation (DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the company’s first commercial product HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]. As part of the restructuring, the company will explore strategic alternatives for its immuno-oncology portfolio and will reduce the company’s workforce and operations to focus resources on HEPLISAV-B commercialization.
The big shareholder groups in Dynavax Technologies Corporation (NASDAQ:DVAX) have power over the company. Large...
A non-biotech investor would think FDA approval is the biggest hurdle for most small biotech companies and would be rewarded by the market. This is why so many small biotech stocks frequently decline in the quarters following the initial euphoria of FDA approval. This is why initial drug rollouts are usually slower and consume more cash that investors expect after the FDA green light is granted.
How do we determine whether Dynavax Technologies Corporation (NASDAQ:DVAX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 7.46% and -3.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Berkeley, California-based company said it had a loss of 62 cents per share. The biopharmaceutical company posted revenue of $5.8 million in the period. Dynavax Technologies shares have fallen 29% ...
First quarter 2019 HEPLISAV-B® net product revenue of $5.6 millionConference call to be held today at 4:30 p.m. ET/1:30 p.m. PT BERKELEY, Calif., May 08, 2019 -- Dynavax.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Dynavax Technologies Corp. (NASDAQ: DVAX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM ...
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines and immuno-oncology therapeutics, today announced the enrollment of the first patient in the company’s open-label, single-arm study of HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis. “Although vaccination to prevent hepatitis B infection has been standard practice for decades for dialysis patients and healthcare workers, there remains a need to provide improved overall protection safely through a greater and more durable antibody response,” said Robert Janssen, M.D., chief medical officer of Dynavax. This open-label, single arm study will evaluate HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis.
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BERKELEY, Calif., April 25, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
BERKELEY, Calif., April 18, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But l...